

Lily Vakili she/her

---

Principal

**E** [lily.vakili@faberlawgroup.com](mailto:lily.vakili@faberlawgroup.com)

**P** (212) 230 5750



Lily guides biotechnology companies in the negotiation of complex product development and commercialization transactions.

She advises early and mid-stage companies, many in the cell and gene-therapy space, and assists drug sponsors and contract development and manufacturing organizations in the negotiation of clinical and commercial manufacturing and supply arrangements.

Lily also represents public and private companies in strategic collaborations, product licensing, and distribution and co-promotion agreements.

From 2020 to 2022, Lily chaired the firm's Equity, Diversity and Inclusion Committee.

**BAR ADMISSIONS**

New York

**EDUCATION**

Harvard Law School, J.D.

University of Minnesota, B.A.,  
summa cum laude, Phi Beta Kappa

# Experience

## Director and Counsel

New York Branch of UBS

- Represented the bank in connection with domestic and international syndicated loan and complex financings

## Corporate Department Associate

Simpson Thacher & Bartlett

- Represented international and domestic lending institutions and borrowers in connection with banking and project finance transactions

## Member of business transactions group

Sidley Austin

# Client Work

- Advising Intergalactic Therapeutics, a Boston-based company founded by Apple Tree Partners developing a non-viral alternative to viral-based gene therapy, in connection with the establishment of a complex process development and manufacturing supply chain
- Advising Anthos Therapeutics, a clinical-stage biopharmaceutical company focused on treatment of cardiovascular and metabolic diseases, in the negotiation of a global supply chain arrangement for process development and manufacturing of a proprietary drug product
- Representation of Hovione Farmaciencia, an international contract development and manufacturing company, in the negotiation of process development agreements, as well as clinical and commercial manufacturing supply agreements
- Advising Bicara Therapeutics, Inc., a Boston-based clinical-stage biotechnology company developing a pipeline of bifunctional antibodies that exploit recent advances in immuno-oncology, in the establishment of a global development and manufacturing supply chain
- Representation of an investor syndicate led by 5AM Venture Management in the negotiation of a development and manufacturing agreement for clinical supply of an exclusively in-licensed drug product for the treatment of respiratory diseases
- Advising Atara Biotherapeutics with respect to manufacturing and clinical supply documentation in connection with an exclusive license of clinical-stage T-cell therapy technology from Memorial Sloan Kettering Cancer Center

# Community Involvement

- Member - New York City Bar Association's Bioethical Issues Committee
- Member - New York City Bar Association's Science & Law Committee
- Member - Harvard Law School Women's Association of New York
- Panelist - 9th Annual Summit for Women Leaders in Life Sciences Law - Key International Developments Impacting the Global Life Sciences Industry (July 28, 2022)
- Panelist - 7th Annual ACI Conference on Women Leaders in Life Sciences Law - Pre-conference Workshop - Career Advancement Boot Camp: Employing Strategies for Communication, Negotiation and Management (Nov. 16, 2020)
- Speaker - Faber Webinar - Manufacturing Agreements During the COVID-19 Pandemic (May 4, 2020)